原发性胆汁性肝硬化药物治疗进展

doi:10.3969/j.issn.1672-5069.2015.02.032

Abstract

Li Pingying，Lu Lungen. Advances in pharmacotherapy of patients with primary biliary cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(4): 441-444.

[1] Selmi C，Bowlus CL，Gershwin ME，et al. Primary biliary cirrhosis. Lancet，2011，377：1600-1609．
[2] Boberg KM，Wisloff T，Kjollesdal KS，et al. Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid. Aliment Pharmacol Ther，2013，38（7）：794-803.
[3] Poupon R. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases：an overview of their mechanisms of action. Clin Res Hepatol Gastroenterol， 2012，36（Suppl 1）：S3-S12.
[4] Leuschner U，Manns MP，Eisebitt R. Ursodeoxycholic acid in the therapy for primary biliary cirrhosis：effects on progression and prognosis. Z Gastroenterol，2005，43（9）：1051-1059.
[5] Rautiainen H，Karkkainen P，Karvonen AL，et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis：a three-year randomized trial. Hepatology，2005，41（4）：747-752.
[6] Corpechot C，Abenavoli L，Rabahi N，et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology，2008，48：871-877.
[7] Fiorucci S，Cipriani S，Mencarelli A，et al. Farnesoid X receptor agonist for the treatment of liver and metabolic disorders： focus on 6-ethyl-CDCA. Mini Rev Med Chem，2011，11（9）：753-762.
[8] Beuers U，Boberg KM，Chapman RW，et al. EASL Clinical Practice Guidelines：management of cholestatic liver diseases. J Hepatol，2009，51（2）：237-267.
[9] Cash W J， O'Neill S，O'Donnell ME，et al. Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis. Liver Int，2013，33（8）：1166-1174.
[10] Stojakovic T，Putz-Bankuti C，Fauler G，et al. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology，2007，46（3）： 776-784.
[11] Leuschner M， Holtmeier J，Ackermann H，et al. The influence of sulindac on patients with primary biliary cirrhosis that responds incompletely to ursodeoxycholic acid：a pilot study. Eur J Gastroenterol Hepatol，2002，14（12）：1369-1376.
[12] Silveira MG，Lindor KD. Treatment of primary biliary cirrhosis： therapy with choleretic and immunosuppressive agents. Clin Liver Dis，2008，12（2）：425-443.
[13] Rabahi N，Chrétien Y，Gaouar F，et al. Triple therapy with ursodeoxycholic acid，budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone. Gastroenterol Clin Biol，2010，34（4-5）：283-287.
[14] Angulo P，Jorgensen RA，Keach JC，et al. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology，2000，31（2）：318-323.
[15] Silveira MG，Lindor KD. Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis. Expert Opin Pharmacother，2014，15（3）：365-372.
[16] Kaplan MM，Bonder A，Ruthazer R，et al. Methotrexate in patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid. Dig Dis Sci，2010，55（11）：3207-3217.
[17] Giljaca V，Poropat G，Stimac D，et al. Methotrexate for primary biliary cirrhosis. Cochrane Database Syst Rev，2010，12（5）： CD004385
[18] Poupon R. Evidence-based treatment of primary biliary cirrhosis. Dig Dis，2014，32（5）：626-630.
[19] Al-Harthy N，Kumagi T. Natural history and management of primary biliary cirrhosis. Hepat Med，2012，4：61-71.
[20] Gong Y，Christensen E，Gluud C. Azathioprine for primary biliary cirrhosis. Cochrane Database Syst Rev，2007，（3）：CD006000.
[21] Gong Y，Gluud C. Colchicine for primary biliary cirrhosis. Cochrane Database Syst Rev，2004，（2）：CD004481.
[22] Leung J，Bonis PA，Kaplan MM. Colchicine or methotrexate， with ursodiol，are effective after 20 years in a subset of patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol，2011，9（9）：776-80.
[23] Angulo P，Patel T，Jorgensen RA，et al. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology，2000，32（5）： 897-900.
[24] Pares A. Old and novel therapies for primary biliary cirrhosis. Semin Liver Dis，2014，34（3）：341-351.
[25] Bergasa NV，Alling DW，Talbot TL，et al. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis：a controlled study. J Am Acad Dermatol，1999，41（3Pt1）： 431-434.
[26] Bergasa NV，Talbot TL，Alling DW，et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology，1992，102（2）：544-549.
[27] Parés A，Guanabens N. Osteoporosis in primary biliary cirrhosis：pathogenesis and treatment. Clin Liver Dis，2008，12：407-424.
[28] Dempster DW，Lambing CL，Kostenuik PJ，et al. Role of RANK ligand and denosumab，a targeted RANK ligand inhibitor，in bone health and osteoporosis：a review of preclinical and clinical data. Clin Ther，2012，34：521-536.
[29] Hazzan R， Tur-Kaspa R. Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid. J Clin Gastroenterol，2010，44（5）：371-373.
[30] Levy C，Peter JA，Nelson DR，et al. Pilot study： fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther，2011，33（2）：235-242.
[31] Talwalkar JA，Lindor kD. Primary biliary cirrhosis. Lancet， 2003，362：53-61.
[32] Kaplan MM，Bonis PA. Modafinil for the treatment of fatigue in primary biliary cirrhosis. Ann Intern Med，2005，143：546-547.
[33] Mason AL， Lindor KD，Bacon BR，et al. Clinical trial： Randomized controlled trial of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol. Aliment Pharmacol Ther，2008，28（7）：886-894.
[34] Charatcharoenwitthaya P，Talwalkar J A，Angulo P，et al. Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. Dig Dis Sci， 2010，55（2）：476-483.

Advances in pharmacotherapy of patients with primary biliary cirrhosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Xing Xin, Wei Zhongcao, Zhou mimi, et al.. Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis [J]. Journal of Practical Hepatology, 2019, 22(6): 852-855.
[2]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[3]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[4]	Bian Xinqu, Chen Jie, Liu Yanmin, et al. Serum thyroid hormone level changes in patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy [J]. Journal of Practical Hepatology, 2019, 22(5): 716-719.
[5]	Lu Lungen. Cholestatic liver diseases：What we know and how to deal with [J]. Journal of Practical Hepatology, 2019, 22(5): 754-757.
[6]	Liu Yingchuan, Zhao Pengcheng, You Ting, et al.. Changes of peripheral blood 25-（OH） 2-D3 levels and peripheral T lymphocyte subsets in patients with primary biliary cirrhosis receiving vitamin D supplementation and ursodeoxycholic acid treatment [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 907-910.
[7]	Liu Jinguo, Wang Baokui. Efficacy of Fufangbiejia Ruanganpian and ursodeoxycholic acid combination in the treatment of patients with primary biliary cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 340-343.
[8]	Li Min, Li Hong, Fu Zhiyue. Efficacy of adenosylmethionine combined with ursodeoxycholic acid in treatment of infants with cytomegalovirus infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 461-462.
[9]	Qin Wei, Chen Yuping, Yang Zhao, et al. Expression of transforming growth factor β-1 in liver tissues of patients with primary biliary cirrhosis and its relationship with liver fibrosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 237-240.
[10]	Chen Xiaojun, Song Yang. Changes of peripheral blood T lymphocyte subsets and efficacy of ursodesoxycholic acid and vitamin D combination in treatment of patients with primary biliary cholangitis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(1): 80-83.
[11]	Tao Mingling, Zhang Shibin, Wu Yanjing, et al.. Non-invasive predictors of esophageal varices in patients with primary biliary cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(4): 439-442.
[12]	Liu Funa, Liu Jiangkui, Shen Yihui.. Efficacy of ursodeoxycholic acid and prednisolone combination in treatment of patients with primary biliary cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(4): 443-446.
[13]	Jiang Hao, Ge Hongyan.. Clinical efficacy of ursodeoxycholic acid combined with fat-soluble vitamin in treatment of patients with alcoholic liver disease and intrahepatic cholestasis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(1): 105-106.
[14]	Guo Rui, Tan Jin.. A randomized controlled trial of ursodeoxycholic acid in treating patients with primary biliary cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(1): 109-110.
[15]	Han Yongbin， Liu Xin，Wang Aifang， et al.. Primary biliary cirrhosis misdiagnosed as bone marrow hyperplasia syndrome: A case report [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(6): 747-748.